"Shankar
and Gaurav have made exceptional contributions to the firm and the
companies
with whom they work,” said Rod Ferguson, managing director at
Panorama
Capital. "I am enthusiastic about them as partners who will help
lead the firm into the next decade." Both Chandran and Aggarwal
were
previously principals with the firm and will continue to invest in
startups and
help entrepreneurs build market leading, category defining companies.

Shankar
Chandran leads Panorama’s efforts in the core technology sector,
investing in
companies developing the critical components and systems enabling the
convergence of mobile technology and the web. Shankar has been a
principal with
the firm since its founding in 2005 and worked closely with the team
since 2002
at JPMorgan Partners. He currently serves on the board of directors of
Validity,
CHiL Semiconductor and Neoconix. Previously, Shankar was involved
either as a
director or observer with the firm’s investments in Reflectivity
(acquired by
TI), Valere Power (acquired by Eltek) and Portalplayer (acquired by
Nvidia).

Prior
to his venture capital career, Shankar had extensive operating
experience,
holding various engineering, business development, and management roles
at
Applied Materials. He has been granted seven patents. Shankar
serves on
the Advisory Board of Center for Innovation and Entrepreneurship at the
Santa
Clara University and holds a B.Tech in Metallurgical Engineering from
the
Institute of Technology, BHU (India), an M.S. in Materials Science from
Arizona
State University, and an M.B.A. from The Wharton School of the
University of
Pennsylvania.

A
physician by training, Gaurav Aggarwal invests in emerging life
sciences
companies and has been part of the firm as a principal since its
founding. He too worked with the team while at JPMorgan
Partners.
He currently serves on the board of directors of Alvine Pharmaceuticals
and
Hyperion Therapeutics, and was previously on the board of directors at
Flowcardia (acquired by Bard) and PIramed (acquired by Roche).
Gaurav was
also closely involved in the firm’s investments in Amarin
Corporation and
Presidio Pharmaceuticals.

Previously,
Gaurav was at KBL Healthcare Ventures, where he focused on venture
investments
in biopharmaceutical and medical device companies. There he
served as a
board observer with KBL's investments in Achillion Pharmaceuticals,
ISTA
Pharmaceuticals, Neuronetics and Spinal Concepts and was involved with
KBL's
investments in Corixa Corporation and Scynexis. Gaurav received
his M.D.
from Columbia University, College of Physicians & Surgeons and his
B.S. in
Business Management from Cornell University.

About
Panorama Capital

Panorama
Capital is a Silicon Valley venture capital firm that invests in
passionate
entrepreneurs building leading companies in technology and life
sciences.
Panorama takes a hands-on approach to investing, helping companies
accelerate
their growth. We bring to each portfolio company our knowledge as
seasoned investors who also possess a wealth of experience as
executives,
entrepreneurs, engineers and physicians. This experience gives Panorama
Capital
a powerful combination of technical, operational and transactional
expertise to
help our companies succeed. For more than two decades, the
Panorama
Capital team has invested in and helped build more than 100 companies,
more
than 60 of which went public or were acquired. For more
information about
Panorama Capital, visit www.panoramacapital.com.